Pancreatic Cancer Research

ResearcherUniversity of ZurichActive in the last 2 years

Pierre‐Alain Clavien

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9916-7905; OpenAlex author ID A5074488110. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
64
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 1 paper

Papers 9

  1. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  2. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  3. Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy. Co-author DOI 10.3390/cancers15041235↗
  4. Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. Last author DOI 10.1097/sla.0000000000005126↗
  5. "HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer. Co-author DOI 10.1186/s13014-017-0923-8↗
  6. CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-16-0058↗
  7. [Pancreatic cancer- a curable disease]. Last author DOI 10.1024/1661-8157/a001990↗
  8. Extended lymphadenectomy in patients with pancreatic cancer is debatable. Last author DOI 10.1007/s00268-013-2064-z↗
  9. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III s… Last author DOI 10.1186/1471-2407-11-346↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Përparim Limani · 2 shared papers, 2015–2023 · strength 0.25
  2. Mickaël Lesurtel · 4 shared papers, 2011–2021 · strength 0.22
  3. Michelle Lucinda DeOliveira · 3 shared papers, 2013–2021 · strength 0.19
  4. Raefa Abou Khouzam · 1 shared paper, 2023 · strength 0.19
  5. Salem Chouaı̈b · 1 shared paper, 2023 · strength 0.19
  6. Michel Pierre Ducreux · 1 shared paper, 2023 · strength 0.19
  7. Michael B. Wallace · 1 shared paper, 2023 · strength 0.19
  8. Matthew H. G. Katz · 1 shared paper, 2023 · strength 0.12
  9. Raëf Abdallah · 1 shared paper, 2023 · strength 0.12
  10. Jin‐Young Jang · 1 shared paper, 2023 · strength 0.12
  11. Giuseppe Malleo · 1 shared paper, 2023 · strength 0.12
  12. Gregory C. Wilson · 1 shared paper, 2023 · strength 0.12
  13. Ryan K. Schmocker · 1 shared paper, 2023 · strength 0.12
  14. Jin Peng He · 1 shared paper, 2023 · strength 0.12
  15. Sarah Maloney · 1 shared paper, 2023 · strength 0.12
  16. Russell F. Palm · 1 shared paper, 2023 · strength 0.12
  17. John Bart Rose · 1 shared paper, 2023 · strength 0.12
  18. Yoo Jin Choi · 1 shared paper, 2023 · strength 0.12
  19. Hongbeom Kim · 1 shared paper, 2023 · strength 0.12
  20. Klaus Sahora · 1 shared paper, 2023 · strength 0.12
  21. Thomas Malinka · 1 shared paper, 2023 · strength 0.12
  22. Kuno Lehmann · 1 shared paper, 2023 · strength 0.12
  23. Syed Ameen Ahmad · 1 shared paper, 2023 · strength 0.12
  24. Laura Maggino · 1 shared paper, 2023 · strength 0.12
  25. Dilmurodjon Eshmuminov · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.